Amgen Inc.
C-TERMINAL ANTIBODY VARIANTS
Last updated:
Abstract:
The invention generally relates to anti-sclerostin antibodies having C-terminal modifications, and compositions comprising such antibodies.
Status:
Application
Type:
Utility
Filling date:
29 Mar 2019
Issue date:
18 Mar 2021